Founder of Burning Rock, established Burning Rock in 2014, engaged in investment of medical fields; with successful experience in establishing and operating a start-up team; with sixteen years of working experience in the field of life science.
☆ Established Burning Rock
☆ Investment manager of top-rank VC Northern Light Venture Capital
☆ MBA from Columbia University
☆ General manager of BioTek Instrument China Region
☆ Cell biology master of Peking Union Medical College
Co-founder of Burning Rock. With 13 years of experience in the field of bioinformatics and translational medicine, mastered internationally leading technologies, accumulated R& D experience in tumor individualistic diagnosis and treatment related areas such as NGS data analysis, molecular diagnosis,etc.
☆ Novartis (China) R& D Center: Supervisor of the bioinformatics platform
☆ Chief Statistical Analyst of Novartis (America), University of Pennsylvania
☆ Experiment designer and data analyst of Sloan-Katherine Cancer Center of New York
☆ University of Pennsylvania: Biostatistics Ph.D.
☆ University of Texas: Statistics and Applied Mathematics Master
Mr. Leo Li has served as our chief financial officer since the third quarter of 2019 and
our director since the first quarter of 2020.
☆Mr. Li served as an investment director and later an executive director of Vision Knight
Capital, or VKC, a private equity fund focusing on China's internet-driven sectors.
☆ Prior to VKC, Mr. Li worked at Morgan Stanley Asia Ltd.
☆ Mr. Li attended University of Oxford from 2004 to 2008 and received a four-year Master of Physics degree.
☆ Mr. Li is a Chartered Financial Analyst.
With 14 years of clinical R&D experience with a foreign-owned pharmaceutical company. Ever took charge of clinical development of several important declining drugs in China, such as Crizotinib, ceritinib, axitinib, velcade, etc.
☆ Novartis: Took charge of all research strategies and projects of solid tumors in China. A senior person with richest development experience of ALK TKI in China (no one else has the all-course experience in the development of ALK TKI of the first and second generation)
☆ Pfizer: Took charge of all clinical researches of star drug Crizotinib. A soul-level tutor and person in charge of development of Crizotinib in China.
☆ Worked in a tumor hospital of Chinese Academy of Medical Sciences for five years
With working experience in the field of NGS for over 10 years. Ever participated in research and development of several products, successfully released kits such as Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA as a leader of the core team, and made outstanding contribution to the fast development of NGS
☆ A senior scientist of Illumina.
☆ A senior researcher of genome science department of Howard Hughes Institute of Medicine of University of Washington
☆ Duke University: Ph.D. of molecular genetics and microbiology
Vice President for Business Development
With above ten years of experience in life science and medicine and with rich experience in marketing and project management
☆ Co-founder of Burning Rock
☆ Gene Co., Ltd. General manager for China Region with the department of large applied instrument
☆ Gene Co., Ltd. Project manager for China Region (applied industry)
☆ Nanjing Normal University Biotech
Sales Vice President for Tumor Early Detection
Focused on sales of in vitro diagnostic agent for above 16 years, with rich marketing management and business expansion capabilities.
☆ Worked as a sales supervisor for South China region in QIAGEN Business Management (Shanghai) Co., Ltd.
☆ Worked as a market explorer in South China regionBeijing Jinpujia Medical Technology Co., Ltd.
☆ Gene (Hong Kong) Co., Ltd.: Sales of Denmark DAKO, America BD, Abbott VYSIS diagnosis reagent, pathology, streaming and blood departments of Guangdong and Fujian
☆ Shandong Liming Polytechnic Vocational College